0A3S.LSE Novavax Inc.
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2023.
Is 0A3S.LSE undervalued?
Graham numberThe Graham number of Novavax Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Novavax Inc. fundamental analysis
No fundamental analysis for Novavax Inc. yet.
Novavax Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Novavax Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, a…
Full company profileNovavax Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
Novavax Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 15.4M | 31.2M | 34.3M | 18.7M | 476M | - | - | - |
| Operating Income | -269M | -172M | -174M | -121M | -417M | - | - | - |
| Net Income | -280M | -184M | -185M | -133M | -418M | - | - | - |
| Balance Sheet | ||||||||
| Total Assets | - | - | - | - | 1.58B | - | - | - |
| Total Liabilities | - | - | - | - | 955M | - | - | - |
| Shareholders' Equity | - | - | - | - | 627M | - | - | - |
| Cash & Short-term Investments | - | - | - | - | 711M | - | - | - |
| Total Debt | - | - | - | - | 362M | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -259M | -144M | -185M | -137M | -42.5M | 323M | -416M | - |
| Capital Expenditure | 18.2M | 4.19M | 1.37M | 1.86M | 54.5M | 54.5M | 89.1M | 0.00 |
| Ratios | ||||||||
| ROE | - | - | - | - | -66.7% | - | - | - |
| ROA | - | - | - | - | -26.4% | - | - | - |
| Net Profit Margin | -1,823.5% | -589.5% | -538.8% | -711.0% | -87.9% | - | - | - |
| Debt to Equity | - | - | - | - | 0.58x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Novavax Inc. dividends
Novavax Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 0.05:1 on May 10, 2019.
Who owns Novavax Inc.
- Insiders 5.05%
- Institutions 66.71%
- Public & others 28.24%
- Free float 146M
Novavax Inc. company profile
- Company name
- Novavax Inc.
- Ticker
- 0A3S.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 749
- Fiscal year end
- December
- Address
- 21 Firstfield Road, Gaithersburg, MD, United States, 20878
- Phone
- 240 268 2000
- Website
- novavax.com
About Novavax Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax Inc. management
10- Mr. John Charles Jacobs M.B.A.President, CEO & Director · born 1967
- Mr. James Patrick Kelly C.F.A.Executive VP, CFO & Treasurer · born 1966
- Mr. Mark J. Casey Esq., J.D.Executive VP, Chief Legal Officer & Corporate Secretary · born 1963
- Ms. Elaine O'HaraExecutive VP & Chief Strategy Officer · born 1968
- Mr. Richard P. CrowleyExecutive VP & COO · born 1957
- Ms. Naina ZamanDirector of Investor Relations
- Mr. Troy Morgan Esq., J.D.Senior VP, Deputy General Counsel & Chief Compliance Officer · born 1971
- Ms. Erika S. TrahanAssociate Director of Investor & Public Relations
- Mr. Ian J. WatkinsExecutive VP & Chief Human Resources Officer · born 1963
- Ms. Silvia Taylor M.B.A.Executive VP, Chief Corporate Affairs Officer & Head of Novavax Sweden